Cybin AAQS

Co robi Cybin? Cybin Inc, listed under the ticker HELP.NE, is a clinical-stage biopharmaceutical company headquartered in Toronto, Canada. The company went public via an IPO on January 5, 2018. With approximately 50 employees, Cybin focuses on developing psychedelic-based therapeutics to address unmet needs in mental health treatment. The company's research includes studies on N,N-dimethyltryptamine (DMT) and dDMT molecules, aiming to build a comprehensive dataset for these compounds. Cybin is advancing two key programs: CYB003, a proprietary deuterated psilocybin analog for major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder. While the source mentions CYB003 moving to Phase III and CYB004 to Phase II, these developmental stages are not confirmed in the provided data. The company holds an intellectual property portfolio within the psychedelic drug development sector, with over 30 patents granted and 160 patents pending. Cybin operates in multiple countries, including Canada, the United States, the United Kingdom, the Netherlands, and Ireland. The company's website is https://www.cybin.com. As a clinical-stage firm, Cybin is dedicated to pioneering novel therapeutic approaches for mental health conditions through innovative psychedelic research. Cybin jest jedną z najpopularniejszych firm na Eulerpool.